Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field51
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus51
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort50
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children46
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol42
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease39
Towards a minimal core dataset for systemic lupus erythematosus studies38
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus37
Genetic load in incomplete lupus erythematosus34
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort30
Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality30
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms26
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE25
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus25
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus24
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort24
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials23
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory22
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain22
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit22
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response21
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial21
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus21
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort20
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance20
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine19
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated19
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA19
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus18
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards18
Cortical changes in women with systemic lupus erythematosus with mild cognitive impairment: a voxel-based morphometry and surface-based morphometry study17
Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts17
Prevalence and determinants of vertebral fractures in a SLE cohort17
Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis17
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression17
Frequency-dependent and temporal variability of low-frequency fluctuations in patients with primary Sjögren’s syndrome17
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice16
To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus16
Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort16
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden16
Prevalence and predictive factors associated with sustained remission in SLE: a systematic review15
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE15
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study15
Dyspigmentation and scarring in cutaneous lupus erythematosus15
Function of follicular helper 17 T cells in driving B cells for anti-DNA autoantibody production in patients with SLE15
Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort15
Neutrophil gelatinase-associated lipocalin (NGAL) in lupus nephritis and beyond15
Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE15
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups14
Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus14
Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis14
Systematic review of the reporting of extrarenal manifestations in observational studies of Saudi patients with systemic lupus erythematosus14
Canadian patient experiences of lupus nephritis: a qualitative analysis14
Rare and common single nucleotide variants in childhood-onset systemic lupus erythematosus13
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis13
Clinical and immunological differences between primary and autoimmune-associated neuromyelitis optica spectrum disorders: a retrospective study13
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler13
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway13
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development12
Discrepant anti-dsDNA testing between EliA and Crithidia in ANA negative samples: just a false positive?12
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE12
Meeting report: patient and caregiver recommendations for a mobile health application for paediatric systemic lupus erythematosus12
Lupus spectrum ambiguity has long-term negative implications for patients12
Unravelling the TCRβ repertoire: a key to unlocking the immunopathogenesis and precision medicine in SLE12
Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes12
Evaluation of the effects of pre-exposure treatment with hydroxychloroquine on the risk of COVID-19 infection and on the efficacy of anti-COVID-19 vaccination during lupus or Gougerot-Sjögren’s diseas12
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P a11
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study11
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis11
Potential causal effect of SLE on osteoporosis, and the mediation effect: a Mendelian randomisation study11
Treatment trends of systemic lupus erythematosus from 2007 to 2023 in the USA11
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption11
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework11
Association between disease duration and comorbidity burden in systemic lupus erythematosus: a multicentre study from Pakistan11
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study10
Visceral fat, cardiovascular risk factors and quality of life in lupus activity categorised via complement C310
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus10
Genetic relationships between systemic lupus erythematosus and a positive antinuclear antibody test in the absence of autoimmune disease10
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study10
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE10
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density10
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus10
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up10
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history10
Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis10
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry9
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study9
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms9
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?9
Validation of eight endotypes of lupus based on whole-blood RNA profiles9
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-1329
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease9
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)9
Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis9
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica9
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus8
Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms8
Proteins upregulated in thrombotic antiphospholipid syndrome linked to platelet function in contrast with non-antiphospholipid-related thrombosis: insights from two systematic reviews8
Systemic lupus erythematosus comorbid with chronic spontaneous urticaria: a multicentre retrospective study8
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study8
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort8
Dietary Intervention for Systemic Lupus Erythematosus patients based on HLA-DQ2 and DQ8 genotyping (DISH): a protocol for a randomised controlled study8
Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week p8
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus8
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort7
Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus7
Prediction of mortality risk in critically ill patients with systemic lupus erythematosus: a machine learning approach using the MIMIC-IV database7
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study7
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus7
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations7
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial7
HDAC3 knockdown inhibits ferroptosis via upregulating Nrf2 to alleviate renal interstitial fibrosis in lupus nephritis7
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE7
0.084274053573608